IQVIA reported $17.0B of revenue over the trailing twelve months, +8.2% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $17.0B (to Q2 2026). Net income: $1.38B, trailing twelve months to Q2 2026. Free cash flow: $2.18B, trailing twelve months to Q2 2026. Operating margin: 13%, trailing twelve months to Q2 2026.

IQVIQVIA

Healthcare

$279.21+36% 1Y

$279.21

$156.6652 weeks$279.21

Latest close: a new 52-week highOct 23, 2026what changed →

IQV as reported

IQVIA reported $17.0B of revenue over the trailing twelve months, +8.2% on the year before. 11 reported series are charted on this page, each one as filed.

$17.0B

Revenue, trailing twelve months · to Q2 2026 · +8.2% against the twelve months before

Net income: $1.38B
Net income · +11% year on year · trailing twelve months to Q2 2026
Free cash flow: $2.18B
Free cash flow · +8.7% year on year · trailing twelve months to Q2 2026
Operating margin: 13%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for IQV, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$17.0B	+8.2%	Q2 2026
Net income	$1.38B	+11%	Q2 2026
EPS	$8.05	+17%	Q2 2026
Gross margin	33%	n/a	Q2 2026
Operating margin	13%	n/a	Q2 2026
Net margin	8.1%	n/a	Q2 2026
ROE	22%	n/a	Q2 2026
ROA	4.6%	n/a	Q2 2026
ROIC	8.7%	n/a	Q2 2026
Free cash flow	$2.18B	+8.7%	Q2 2026
P/E	34.7	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.